Relapsed/Refractory Clinical Trials

125 recruitingLast updated: June 18, 2026

There are 125 actively recruiting relapsed/refractory clinical trials across 42 countries. Studies span Phase 1, Phase 2, Early Phase 1, Phase 3, Not Applicable, Phase 4. Top locations include Beijing, Beijing Municipality, China, Shanghai, Shanghai Municipality, China, Wuhan, Hubei, China. Updated daily from ClinicalTrials.gov.


Relapsed/Refractory Trials at a Glance

125 actively recruiting trials for relapsed/refractory are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 1 with 58 trials, with the heaviest enrollment activity in Beijing, Shanghai, and Wuhan. Lead sponsors running relapsed/refractory studies include Beijing Boren Hospital, Nanjing Legend Biotech Co., and Regeneron Pharmaceuticals.

Browse relapsed/refractory trials by phase

Treatments under study

About Relapsed/Refractory Clinical Trials

Looking for clinical trials for Relapsed/Refractory? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Relapsed/Refractory trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Relapsed/Refractory clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 125 trials

Recruiting
Phase 3

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled18 locationsNCT07104032
Recruiting

Individualized AML Treatment

Relapsed/Refractory Acute Myeloid Leukemia (AML)
City of Hope Medical Center18 enrolled1 locationNCT07613385
Recruiting
Phase 3

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Phase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeOne Medicines780 enrolled277 locationsNCT05100862
Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium300 enrolled89 locationsNCT05160584
Recruiting
Early Phase 1

A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

Relapsed/Refractory Large B-Cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.12 enrolled6 locationsNCT07606937
Recruiting
Early Phase 1

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

AL AmyloidosisSystemic Light Chain AmyloidosisRelapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT07626476
Recruiting
Phase 1

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07309900
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Relapsed/Refractory Acute Myeloid Leukemia
SystImmune Inc.120 enrolled18 locationsNCT06714591
Recruiting
Phase 1

Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

Relapsed/Refractory Multiple Myeloma
Peter MacCallum Cancer Centre, Australia12 enrolled1 locationNCT07541391
Recruiting
Phase 2

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Liling Zhang40 enrolled1 locationNCT06867536
Recruiting
Phase 1Phase 2

A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma

Relapsed/Refractory Glioma
The First Affiliated Hospital of Zhengzhou University29 enrolled1 locationNCT07599371
Recruiting
Phase 1

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University30 enrolled6 locationsNCT07002112
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled84 locationsNCT04973605
Recruiting
Phase 1Phase 2

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb240 enrolled11 locationsNCT07325136
Recruiting
Phase 1Phase 2

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Locally AdvancedUnresectableMetastatic Cancers+1 more
Recursion Pharmaceuticals Inc.170 enrolled6 locationsNCT06678659
Recruiting
Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Relapsed/Refractory Follicular LymphomaRelapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Regeneron Pharmaceuticals470 enrolled169 locationsNCT06149286
Recruiting
Phase 1Phase 2

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1

Autologous CD19-CD20-NKG2D-nsBicephali CAR-T for Relapsed/Refractory Central Nervous System Lymphoma

Relapsed/Refractory Primary Central Nervous System LymphomaRelapsed/Refractory Central Nervous System LymphomaRelapsed/Refractory Secondary Central Nervous System Lymphoma
Beijing Boren Hospital30 enrolled1 locationNCT07555561
Recruiting
Phase 1

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Relapsed/Refractory Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled2 locationsNCT07249879